KIR2DL1

Across TCGA pan-cancer cohorts, KIR2DL1 Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated KIR2DL1 data layer compared with 23 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in uterine carcinosarcoma (UCS), where higher KIR2DL1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated KIR2DL1 expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

UCS, UCEC, and KIRC are the cancer types where KIR2DL1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCS	DFS	Median	All	0.068	0.524	<.001	48	view →
UCEC	DFS	Median	All	1.000	0.625	.009	32	view →
KIRC	DFS	Median	II,III,IV	0.062	0.762	<.001	18	view →
BRCA	OS	Median	III,IV	0.198	0.833	<.001	16	view →
SARC	OS	Median	All	0.149	0.515	.043	6	view →
PAAD	DFS	Median	All	0.112	0.504	.025	6	view →
SKCM	DFS	Median	All	0.160	0.219	.005	6	view →
STAD	DFS	Median	II,III,IV	1.000	0.327	.040	5	view →
BLCA	DFS	Median	All	1.000	0.501	.042	4	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

KIR2DL1–UCS (DFS)

Open the UCS breakdown →